Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

Overview of attention for article published in Liver International, March 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 12 X users
facebook: 2 Facebook pages

guideline: 1 clinical guideline source

Readers on

mendeley: 83 Mendeley

So far, Altmetric has seen 17 X posts from 12 X users, with an upper bound of 15,235 followers.

RT @APAHEuruguay: #Daclatasvir más SOF con o sin RBV para #HCV genotipo 3 en un programa de acceso precoz #Frances Sin beneficio en los tra…

RT @APAHEuruguay: #Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitisC virus #GT 3 in French early access programme http…

RT @APAHEuruguay: #Daclatasvir más SOF con o sin RBV para #HCV genotipo 3 en un programa de acceso precoz #Frances Sin beneficio en los tra…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 13 additional X posts.